• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishGo to App
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form SC 13G/A filed by Burning Rock Biotech Limited (Amendment)

    2/9/24 8:01:27 PM ET
    $BNR
    Medical Specialities
    Health Care
    Get the next $BNR alert in real time by email
    SC 13G/A 1 ef20021275_sc13ga.htm SC 13G/A
    UNITED STATES
    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549

    SCHEDULE 13G

    Under the Securities Exchange Act of 1934
    (Amendment No. 2) *

    Burning Rock Biotech Limited


    (Name of Issuer)

    American depositary shares, each representing one Class A ordinary share, par value US$0.0002 per share


    (Title of Class of Securities)

    12233L107


    (CUSIP Number)


    December 31, 2023


    (Date of the Event Which Requires Filing of this Statement)

    Check the appropriate box to designate the rule pursuant to which this Schedule is filed :

    ☐ Rule 13d-1(b)
    ☒  Rule 13d-1(c)
    ☐Rule 13d-1(d)

    * The remainder of this cover page shall be filled out for a reporting person’s initial filing on this form with respect to the subject class of securities, and for any subsequent amendment containing information which would alter the disclosures provided in a prior cover page.

    The information required in the remainder of this cover page shall not be deemed to be “filed” for the purpose of Section 18 of the Securities Exchange Act of 1934 (“Act”) or otherwise subject to the liabilities of that section of the Act but shall be subject to all other provision of the Act (however, see the Notes).



    SCHEDULE 13G
    CUSIP No. 12233L107
    Page 2 of 8 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    GIC Private Limited
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Republic of Singapore
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    217,825
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    3,838,575
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    217,825
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    3,838,575
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    4,056,400
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    4.75% (1)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     
     

    (1) Based on 85,350,544 Class A ordinary shares outstanding as of March 31, 2023, according to the Form 20-F filed by the Issuer with the Securities and Exchange Commission on April 20, 2023.


    SCHEDULE 13G
    CUSIP No. 12233L107
    Page 3 of 8 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    GIC Special Investments Private Limited
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Republic of Singapore
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    3,760,650
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    3,760,650
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    3,760,650
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    4.41% (1)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     


    (1) Based on 85,350,544 Class A ordinary shares outstanding as of March 31, 2023, according to the Form 20-F filed by the Issuer with the Securities and Exchange Commission on April 20, 2023.

    SCHEDULE 13G
    CUSIP No. 12233L107
    Page 4 of 8 Pages
    1
    NAMES OF REPORTING PERSONS
     
     
    Owap Investment Private Limited
     
     
     
     
    2
    CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP
       
    (a)☐
       
    (b)☐
     
     
    3
    SEC USE ONLY
     
     
     
     
     
     
     
    4
    CITIZENSHIP OR PLACE OF ORGANIZATION
     
     
    Republic of Singapore
     
     
     
     
    NUMBER OF SHARES BENEFICIALLY OWNED BY EACH REPORTING PERSON WITH
    5
    SOLE VOTING POWER
     
     
    0
     
     
     
     
    6
    SHARED VOTING POWER
     
     
    3,760,650
     
     
     
     
    7
    SOLE DISPOSITIVE POWER
     
     
    0
     
     
     
     
    8
    SHARED DISPOSITIVE POWER
     
     
    3,760,650
     
     
     
     
    9
    AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
     
     
    3,760,650
     
     
     
     
    10
    CHECK IF THE AGGREGATE AMOUNT IN ROW (9) EXCLUDES CERTAIN SHARES (SEE INSTRUCTIONS)
     
     
    ☐
     
     
     
     
    11
    PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (9)
     
     
    4.41% (1)
     
     
     
     
    12
    TYPE OF REPORTING PERSON (SEE INSTRUCTIONS)
     
     
    CO
     
     
     
     


    (1) Based on 85,350,544 Class A ordinary shares outstanding as of March 31, 2023, according to the Form 20-F filed by the Issuer with the Securities and Exchange Commission on April 20, 2023.


    SCHEDULE 13G
    CUSIP No. 12233L107
    Page 5 of 8 Pages
    Item 1(a)
    Name of Issuer

    Burning Rock Biotech Limited

    Item 1(b)
    Address of Issuer’s Principal Executive Offices

    No. 5, Xingdao Ring Road North, International Bio Island,
    Guangzhou, 510005
    The People’s Republic of China

    Item 2(a)
    Name of Persons Filing

    GIC Private Limited
    GIC Special Investments Private Limited
    Owap Investment Private Limited

    Item 2(b)
    Address of Principal Business Office or, if none, Residence

    168 Robinson Road
    #37-01 Capital Tower
    Singapore 068912

    Item 2(c)
    Citizenship

    GIC Private Limited – Republic of Singapore
    GIC Special Investments Private Limited – Republic of Singapore
    Owap Investment Private Limited – Republic of Singapore

    Item 2(d)
    Title of Class of Securities

    American depositary shares, each representing one Class A ordinary share, par value US$0.0002 per share

    Item 2(e)
    CUSIP Number

    12233L107

    Item 3
    If this statement is filed pursuant to §§240.13d-1(b), or 13d-2(b) or (c), check whether the person filing is a:

    Not applicable.

    Item 4
    Ownership

    Ownership information with respect to GIC Private Limited, GIC Special Investments Private Limited and Owap Investment Private Limited are incorporated by reference through items (5) through (9) and (11) of the cover page for each entity.
     
    Owap Investment Private Limited shares the power to vote and the power to dispose of 3,760,650 American depositary shares held directly by it with GIC Special Investments Private Limited and GIC Private Limited. GIC Special Investments Private Limited is wholly owned by GIC Private Limited and is the private equity investment arm of GIC Private Limited.
     
    GIC Private Limited is a fund manager and only has two clients – the Government of Singapore (“GoS”) and the Monetary Authority of Singapore (“MAS”).  Under the investment management agreement with GoS, GIC Private Limited has been given the sole discretion to exercise the voting rights attached to, and the disposition of, any shares managed on behalf of GoS.  As such, GIC Private Limited has the sole power to vote and power to dispose of the 217,825 American depositary shares beneficially owned by it.  GIC Private Limited shares power to vote and dispose of 77,925 American depositary shares beneficially owned by it with MAS.


    SCHEDULE 13G
    CUSIP No. 12233L107
    Page 6 of 8 Pages
    Item 5
    Ownership of Five Percent or Less of a Class

    If this statement is being filed to report the fact that as of the date hereof the Reporting Persons have ceased to be the beneficial owners of more than five percent of the class of securities, check the following ☒.

    Item 6
    Ownership of More than Five Percent on Behalf of Another Person

    Not applicable.

    Item 7
    Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company

    Not applicable.

    Item 8
    Identification and Classification of Members of the Group

    Not applicable.

    Item 9
    Notice of Dissolution of Group

    Not applicable.

    Item 10
    Certifications

    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under §240.14a-11.
     

    SCHEDULE 13G
    CUSIP No. 12233L107
    Page 7 of 8 Pages
    SIGNATURE

    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct as of the date below.

     
    GIC PRIVATE LIMITED
     
         
     
    By:
    /s/ Diane Liang Weishan
     
     
    Name:
    Diane Liang Weishan
     
     
    Title:
    Senior Vice President
     
     
    Date:
    February 9. 2024
     
           
     
    By:
    /s/ Toh Tze Meng
     
     
    Name:
    Toh Tze Meng
     
     
    Title:
    Senior Vice President
     
     
    Date:
    February 9, 2024
     
           
     
    GIC SPECIAL INVESTMENTS PRIVATE LIMITED
     
         
     
    By:
    /s/ Jo-Ann Khor Huey Ming
     
     
    Name:
    Jo-Ann Khor Huey Ming
     
     
    Title:
    Authorized Signatory
     
     
    Date:
    February 9, 2024
     
           
     
    OWAP INVESTMENT PRIVATE LIMITED
     
         
     
    By:
    /s/ Holger Dirk Michaelis
     
     
    Name:
    Holger Dirk Michaelis
     
     
    Title:
    Director
     
     
    Date:
    February 9, 2024
     


    SCHEDULE 13G
    CUSIP No. 12233L107
    Page 8 of 8 Pages
    LIST OF EXHIBITS

    Exhibit
     
    Description
         
    A
     
    Joint Filing Agreement


    Get the next $BNR alert in real time by email

    Crush Q1 2026 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $BNR

    DatePrice TargetRatingAnalyst
    10/15/2021Outperform
    Cowen
    7/14/2021$39.94Outperform
    CICC
    More analyst ratings

    $BNR
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cowen resumed coverage on Burning Rock Biotech

    Cowen resumed coverage of Burning Rock Biotech with a rating of Outperform

    10/15/21 7:18:12 AM ET
    $BNR
    Medical Specialities
    Health Care

    CICC initiated coverage on Burning Rock Biotech with a new price target

    CICC initiated coverage of Burning Rock Biotech with a rating of Outperform and set a new price target of $39.94

    7/14/21 5:44:04 AM ET
    $BNR
    Medical Specialities
    Health Care

    $BNR
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Burning Rock Announces 2025 Annual General Meeting to be Held on December 23, 2025

    GUANGZHOU, China, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting ("AGM") on December 23, 2025 at 10:30 a.m. (local time) at the Company's Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai. The notice of the AGM and the form of proxy for the AGM are available on the Company's website, within Investors Relation section, at https://ir.brbiotech.com. The

    12/1/25 4:11:55 AM ET
    $BNR
    Medical Specialities
    Health Care

    Burning Rock Reports Third Quarter 2025 Financial Results

    GUANGZHOU, China, Nov. 20, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock")), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended September 30, 2025. Recent Business Updates Therapy Selection Presented study results at the Cell Reports Medicine on esophageal squamous cell carcinoma in September 2025. "Integrating ctDNA with clinical response evaluation improves residual disease detection post-neoadjuvant chemoradiotherapy to support organsparing strategies and that postoperative ctDNA stratifies recurrence

    11/20/25 1:52:58 AM ET
    $BNR
    Medical Specialities
    Health Care

    Burning Rock's OncoGuide™ OncoScreen™ Plus CDx System Now Approved in Japan as a Companion Diagnostic for Capivasertib in Breast Cancer

    TOKYO and GUANGZHOU, China, Sept. 24, 2025 (GLOBE NEWSWIRE) -- Riken Genesis Co., Ltd. (Riken Genesis) and Burning Rock Biotech Limited (NASDAQ:BNR, "Burning Rock")) today announced that the OncoGuide™ OncoScreen™ Plus CDx System based on OncoScreen™ Plus to be used as a companion diagnostic for AstraZeneca's capivasertib has received Manufacturing and Marketing Approval from Japan's Ministry of Health, Labour and Welfare (MHLW). The CDx System is a combination medical device consisting of the OncoGuide™ OncoScreen™ Plus CDx Kit and the OncoGuide™ OncoScreen™ Plus CDx Analysis Program, designed to be used with a next-generation sequencer. It enables the detection of PIK3

    9/24/25 2:42:42 AM ET
    $BNR
    Medical Specialities
    Health Care

    $BNR
    SEC Filings

    View All

    SEC Form 6-K filed by Burning Rock Biotech Limited

    6-K - Burning Rock Biotech Ltd (0001792267) (Filer)

    12/1/25 9:56:48 AM ET
    $BNR
    Medical Specialities
    Health Care

    SEC Form 6-K filed by Burning Rock Biotech Limited

    6-K - Burning Rock Biotech Ltd (0001792267) (Filer)

    11/20/25 6:05:02 AM ET
    $BNR
    Medical Specialities
    Health Care

    SEC Form 6-K filed by Burning Rock Biotech Limited

    6-K - Burning Rock Biotech Ltd (0001792267) (Filer)

    9/8/25 6:06:26 AM ET
    $BNR
    Medical Specialities
    Health Care

    $BNR
    Financials

    Live finance-specific insights

    View All

    Burning Rock Reports First Quarter 2024 Financial Results

    GUANGZHOU, China, May 29, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months ended March 31, 2024. Recent Business Updates Early Detection THUNDER study for 6-cancer test was included in the Diagnosis and Treatment Guidelines for Primary Liver Cancer (2024 Edition) and the Expert Consensus on Detection and Clinical Application of Tumor DNA Methylation Markers (2024 Edition), showing an impressive performance of ELSA-seq using cfDNA in cancer detection an

    5/29/24 1:34:06 AM ET
    $BNR
    Medical Specialities
    Health Care

    Burning Rock Schedules First Quarter of 2024 Earnings Release on May 29, 2024

    GUANGZHOU, China, May 23, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it plans to release its unaudited financial results for the first quarter of 2024 before the U.S. market opens on May 29, 2024. Following the release, company management will host a conference call at 8:00 a.m. ET (8:00 p.m. Hong Kong time) on the same day to discuss its financial results for the first quarter of 2024. Please register in advance of the conference using the link provided below and dial in 15 minutes prio

    5/23/24 2:00:00 AM ET
    $BNR
    Medical Specialities
    Health Care

    Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results

    GUANGZHOU, China, March 28, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"))), a company focused on the application of next generation sequencing (NGS) technology in the field of precision oncology, today reported financial results for the three months and the year ended December 31, 2023. 2023 Business Overview and Recent Updates Corporate Updates Completed profitability-driven organizational optimization, execution towards profitability well underway Early Detection   Following the Breakthrough Device Designation granted by the US Food and Drug Administration (FDA) for our OverC™ Multi-Cancer Detection

    3/28/24 5:16:22 PM ET
    $BNR
    Medical Specialities
    Health Care

    $BNR
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    Amendment: SEC Form SC 13G/A filed by Burning Rock Biotech Limited

    SC 13G/A - Burning Rock Biotech Ltd (0001792267) (Subject)

    11/14/24 12:29:09 PM ET
    $BNR
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Burning Rock Biotech Limited (Amendment)

    SC 13G/A - Burning Rock Biotech Ltd (0001792267) (Subject)

    2/14/24 4:05:59 PM ET
    $BNR
    Medical Specialities
    Health Care

    SEC Form SC 13G/A filed by Burning Rock Biotech Limited (Amendment)

    SC 13G/A - Burning Rock Biotech Ltd (0001792267) (Subject)

    2/14/24 12:45:51 PM ET
    $BNR
    Medical Specialities
    Health Care

    $BNR
    Leadership Updates

    Live Leadership Updates

    View All

    Burning Rock Announces 2025 Annual General Meeting to be Held on December 23, 2025

    GUANGZHOU, China, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting ("AGM") on December 23, 2025 at 10:30 a.m. (local time) at the Company's Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai. The notice of the AGM and the form of proxy for the AGM are available on the Company's website, within Investors Relation section, at https://ir.brbiotech.com. The

    12/1/25 4:11:55 AM ET
    $BNR
    Medical Specialities
    Health Care

    Burning Rock Announces Results of 2024 Annual General Meeting

    GUANGZHOU, China, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that all shareholder resolutions proposed at the Company's 2024 annual general meeting held today were duly passed. Specifically, the shareholders passed the following resolutions: as an ordinary resolution, THAT the appointment of Ernst & Young Hua Ming LLP as auditor of the Company for the fiscal year ending December 31, 2024 be ratified and that the directors of the Company be authorize

    12/31/24 4:56:17 AM ET
    $BNR
    Medical Specialities
    Health Care

    Burning Rock Announces 2024 Annual General Meeting to be Held on December 31, 2024

    GUANGZHOU, China, Dec. 03, 2024 (GLOBE NEWSWIRE) -- Burning Rock Biotech Limited (NASDAQ:BNR, the "Company" or "Burning Rock"), the "Company" or "Burning Rock"), a company focusing on the application of next generation sequencing (NGS) technology in the field of precision oncology, today announced that it will hold its annual general meeting ("AGM") on December 31, 2024 at 10:00 a.m. (local time) at the Company's Shanghai office at 6/F, Building 10C, Pujiang Smart Plaza, No. 2168 Chenhang Highway, Minhang District, Shanghai. The notice of the AGM and the form of proxy for the AGM are available on the Company's website, within Investors Relation section, at https://ir.brbiotech.com. The AG

    12/3/24 6:45:12 AM ET
    $BNR
    Medical Specialities
    Health Care